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ABSTRACT 
Peripheral infections induce prolonged and exaggerated neuroinflammatory responses in the aged 
brain that result in cognitive impairment, neuropsychiatric complications and ultimately, increased 
mortality rates. Impaired bidirectional communication between microglia and astrocytes, the 
primary immune cells of the brain, contributes to a pro-inflammatory microglial phenotype that 
underlies exacerbated neuroinflammation and sickness behavior. Microglia signal to astrocytes 
with interleukin (IL)-10; in response, astrocytes regulate microglia with transforming growth 
factor beta (TGFβ). Aged microglia produce increased levels of both pro- and anti-inflammatory 
cytokines. However, aged astrocytes exhibit decreased IL-10 receptor (IL-10Rα) expression and 
are less sensitive to IL-10 signaling. In turn, aged astrocytes produce less TGFβ and are unable to 
properly attenuate microglial inflammation. We hypothesized that age-associated impairment of 
this signaling pathway underlies the peripherally induced exaggerated sickness response. Cre/lox 
recombination was used to cross Aldh1l1-CreERT2 and Il10raflox/flox mouse lines to conditionally 
knockout astrocytic Il10ra upon tamoxifen administration and recapitulate an aged-like 
phenotype. Concurrently, adeno-associated virus (AAV)-mediated gene therapy was administered 
directly to astrocytes in the hippocampus of aged mice to augment TGFβ signaling. Mice were 
administered lipopolysaccharide to induce a peripheral immune response. Social behavioral testing 
was followed by characterization of glial mRNA via real-time polymerase chain reaction (qPCR). 
Knockout of Il10ra in adult astrocytes impaired astrocytic TGFβ-mediated attenuation of 
microglia, inducing prolonged and exaggerated neuroinflammation and depressive-like sickness 
behavior. In aged mice, virally augmenting astrocytic TGFβ ameliorated age-associated 
exaggeration of inflammatory sickness response to peripheral immune challenge. Together these 
data implicate this pathway as a potential therapeutic target in resolving cognitive and 
neuropsychiatric complications stemming from peripheral infections in the elderly.  
INTRODUCTION 
The consequences of normal aging on the ability of elderly individuals to respond to peripheral 
infections presents a salient problem for a rapidly aging global population [1, 2, 3]. The efficacy 
of the body’s physiological response to challenges of the peripheral innate immune system declines 
with age, underscored by alteration of bidirectional communication between the immune system 
and nervous system [4, 5]. The aged brain maintains a pro-inflammatory signature “primed” to 
elicit exaggerated and prolonged neuroinflammatory responses upon inductions of peripheral 
infections such as bacterial and viral infections [6, 7, 8]. The hyperinflammatory response of the 
central nervous system (CNS) leaves elderly persons more susceptible to myriad adverse long-
term outcomes, including neuropsychiatric complications, cognitive impairment, and ultimately, 
increased mortality rates [4, 9, 10, 11, 12]. Furthermore, age-associated delirium following acute 
peripheral stimuli is a trademark risk factor for pathologies such as depression, cognitive 
dysfunction, and neurodegenerative diseases such as Alzheimer’s Disease and Parkinson’s Disease 
[13, 14, 15, 16, 17, 18]. Elucidating the mechanisms of breakdown in neuro-immune 
communication that contribute to exacerbated neuropsychiatric outcomes of peripheral infections 
is key to better understanding age-associated immunosenescence and mitigating subsequent 
hyperinflammation in the CNS. 
Microglia and astrocytes, glial cell types in the CNS with immune functions, serve a key 
role in interpreting signaling from the peripheral immune system and inducing a CNS response to 
peripheral stimuli [19, 20, 21]. Moreover, peripheral immune challenges elicit robust 
neuroinflammation and pro-inflammatory cytokine-induced sickness behavior, a phenotype 
recapitulated and well-characterized in rodent models [22, 23, 24, 25, 26, 27]. With age, microglia 
and astrocytes adopt a more pro-inflammatory, or “primed”, profile that lends to more exaggerated 
neuroinflammatory responses to peripheral immune challenges [28, 29, 30, 31]. Furthermore, 
recent findings from our lab demonstrated that microglial repopulation is insufficient to ameliorate 
this primed state, with the aged brain microenvironment a chief influence on conditioning the 
microglia to adopt a primed phenotype [6]. Microglial interaction with aged astrocytes serves as 
an area of interest in elucidating the mechanisms by which the aged brain microenvironment 
contributes to this conditioning effect. Bidirectional communication between microglia and 
astrocytes has been implicated as an important factor in maintaining homeostatic function in the 
central nervous system; in particular, microglia produce anti-inflammatory interleukin (IL)-10  that 
binds to astrocytic IL-10 receptor and induces astrocytic transforming growth factor beta (TGFβ) 
signaling which, in turn, attenuates microglial activation and associated neuroinflammation [32, 
33, 34, 35, 36]. Aged brains exhibit insensitivity to IL-10 signaling as a result of decreased IL-10 
receptor (IL-10Rα) expression [37]. Consequently, through an intracellular signaling cascade, 
transcription and production of functional TGFβ decreases and impairs astrocytic regulation of 
microglia, facilitating exaggerated and prolonged neuroinflammation following challenge to the 
peripheral innate immune system in an ex vivo model of glial interaction [32, 38]. Gaining a better 
understanding of the microglia-astrocyte IL-10/TGFβ signaling pathway and its impact on 
neuroimmune responses to peripheral infections is crucial to identifying potential targets for 
treating and preventing age-associated peripherally induced dysfunction. 
In this study, we sought to utilize a novel in vivo transgenic model of IL-10 receptor 
dysfunction to characterize the genetic and functional neurobehavioral profile of age-associated 
IL-10Rα insensitivity. We then aimed to establish a viable gene therapy to mitigate impairment of 
the IL-10/TGFβ pathway and ameliorate age-associated exaggeration and prolongation of 
peripherally induced neuroinflammation. Here, we provide novel evidence that astrocytic IL-10 
receptor dysfunction is necessary and sufficient for adults to adopt an aged-like phenotype of 
exaggerated and prolonged neuroinflammation and sickness behavior following acute peripheral 
immune challenge. Furthermore, virus-mediated gene therapy augments TGFβ in the aged brain 
to attenuate age-associated microglial activation and resolve subsequent neuroinflammation and 
sickness behavior. 
 
METHODS 
Mice: All procedures and experiments were performed in accordance with the National Institute 
of Health Guide for the Care and Use of Laboratory Animals and were approved by The Ohio 
State University Institutional Animal Care and Use Committee (IACUC). All mice were provided 
ad libitum access to water and standard rodent chow and experienced a standard light/dark cycle. 
Adult (6-8 weeks old) and aged (16-18 months old) male BALB/c mice were purchased from 
Charles River (Wilmington, MA) and singly housed to prevent fighting. 
 
Cre/lox recombination and breeding: Transgenic mice were purchased from The Jackson 
Laboratory. Male B6;FVB-Tg(Aldh1l1-Cre/ERT2)1Khakh/J mice (Aldh1l1-Cre/ERT2; JAX 
029655) were crossed with female B6(SJL)-Il10ratm1.1Tlg/J mice (IL-10Rαflox; JAX 028146). The 
resulting Cre+ offspring were crossed and the offspring genotyped for Cre and Il10raWT/flox 
expression. Finally, Cre+ Il10raflox/flox mice were crossed with Cre- Il10raflox/flox mice to yield a 1:1 
ratio of Cre+:Cre- Il10raflox/flox offspring. Litters were separated by sex into cages of 2-5 mice and 
genotyped for Cre expression at post-natal day 21 (P21). All transgenic mice were administered 
1.5 mg intraperitoneal (i.p.) tamoxifen in corn oil (10 mg/mL) for five consecutive days three 
weeks prior to experimentation to induce Cre-Lox recombination in Cre+ mice. 
 
Peripheral immune challenge with lipopolysaccharide: Adult transgenic mice received a single 
intraperitoneal (i.p.) injection of saline or 0.50 mg/kg Escherichia coli lipopolysaccharide (LPS; 
serotype 0127:B8; Sigma-Aldrich) as a model of peripheral immune challenge. This LPS dosage 
was selected because it elicits a pro-inflammatory cytokine response in the brain resulting in a 
transient sickness response in adult C57BL/6 mice [39]. Similarly, adult and aged BALB/c mice 
received LPS at a dose of 0.33 mg/kg. This dosage was selected because it elicits a pro-
inflammatory cytokine response in the brain resulting in a transient sickness response in adult 
BALB/c mice without mortality in aged mice [6, 7, 26]. 
 
Social exploratory behavior: Social exploration was determined as a measure of sickness behavior 
as previously described [6]. In brief, test subjects were recorded for baseline social exploratory 
activity upon introduction of a novel male juvenile mouse to their home cage for 5 min, then 
injected (t = 0) i.p. with saline or LPS. At t = 4, 8, and 24 h, the social exploration behavioral assay 
was repeated. Behavior was recorded and the total duration of time the experimental subject 
engaged in social investigation of the juvenile (e.g. anogenital sniffing, trailing) was determined. 
At t = 8 h, all nesting material was removed from each cage and replaced with a fresh cotton 
nestlet. At t = 24 h, the provided fresh nestlet was weighed to determine nesting behavior. Mice 
were euthanized at either t = 4 or 24 h. Social index for mice euthanized at t = 24 h was calculated 
as the normalized area under the curve for social interaction (% baseline) v. time post-injection. 
 
Isolation of Percoll-enriched glia: Microglia were isolated from brain homogenates using a Percoll 
density gradient as previously described [6]. In brief, mice were sacrificed by CO2 asphyxiation. 
Brains were collected after decapitation, a 1-mm coronal brain section (Bregma - 1.5 mm) or the 
hippocampus harvested and frozen in liquid nitrogen, and the remaining brain tissue homogenized 
in ice-cold phosphate-buffered saline (PBS) using a 10-mL Potter-Elvehjem tissue grinder 
(Wheaton). The resulting cell pellet was resuspended in 70% isotonic Percoll (GE Healthcare) and 
a discontinuous Percoll density gradient was layered and centrifuged at 2,000×g for 20 min. 
Enriched microglia were collected from the interface between the 70% and 50% Percoll layers. Of 
the cells collected from this interface, >80% of the cells were CD11b+/CD45low microglia. 
Enriched astrocytes were collected from the interface between the 50% and 35% Percoll layers. 
 
Quantification of gene expression by qPCR: RNA was isolated from coronal brain sections and 
hippocampi using the Tri-Reagent protocol (Sigma-Aldrich) and from Percoll-enriched microglia 
using the RNeasy Mini Plus kit (QIAGEN). Reverse transcription was performed using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) to produce cDNA. Quantitative 
real-time (q)-PCR was performed using the TaqMan Gene Expression Assay (Applied 
Biosystems). In brief, experimental cDNA was amplified using qPCR such that a target gene and 
reference gene (Gapdh) were amplified simultaneously using an oligonucleotide probe with a 5’ 
fluorescent reporter dye (FAM) and 3’ non-fluorescent quencher (NFQ). When Taq DNA 
polymerase synthesizes a new strand and reaches the TaqMan probe, the FAM is cleaved from the 
NFQ and increases the fluorescent intensity proportional to the amount of amplicon synthesized. 
Fluorescence was determined using a QuantStudio 5 Real-Time PCR System (Applied 
Biosystems). Data were analyzed using the comparative threshold cycle (ΔΔCT) method and 
results are expressed as fold change from a control group. 
 
Adeno-associated viral vectors: The following adeno-associated viruses (AAVs) were purchased 
from Vector BioLabs. The AAV5-GFAP(0.7)-eGFP (AAV-GFP) consists of an AAV5 capsid with 
AAV2 ITR. The virus expresses enhanced green fluorescent protein (eGFP) under a shortened 0.7-
kB GFAP promoter. The AAV5-GFAP(0.7)-mTGFb1(C223S/C225S)-IRES-GFP (AAV-TGFβ) 
consists of an AAV5 capsid with AAV2 ITR. The virus expresses eGFP alongside mouse Tgfb1 
with two point mutations (C223S and C225S; RefSeq# NM_011577) under the same GFAP(0.7) 
promoter. These mutations render the produced TGFβ1 protein biologically active. 
 
Intra-cerebral hippocampal injection of AAV vectors: Adult and aged male BALB/c mice were 
anesthetized with 5% isoflurane induction, placed in the stereotaxic frame (David Kopf 
Instruments), and maintained at 1.0-1.5% isoflurane during surgery. The skull was exposed and 
coordinates for craniotomy were precisely located by a motorized stereotactic instrument (David 
Kopf Instruments). The following coordinates were used for bilateral hippocampal injections: -
1.82 mm AP, ±1.57 ML, and +1.85 DV. A small hole was drilled through the skull above these 
coordinates and a 10-μL Hamilton syringe slowly lowered into the brain. AAV vectors were 
injected at 1010 GC per 2-μL injection per hemisphere at a rate of 0.4 μL/min. The needle was left 
in place for an additional 1 min and then slowly withdrawn. Wounds were closed with surgical 
staples and mice returned to their home cages for recovery. 
 
Detection of hippocampal TGFβ protein: Hippocampal tissue was sonicated in 300 μL Tissue 
Protein Extraction Reagent (Thermo) supplemented 1:100 with proteinase inhibitor. Hippocampal 
TGFβ protein was then detected using the Mouse TGF Beta 1 ELISA Kit PicoKineTM (Boster) 
according to manufacturer’s protocols. Optical density absorbance was measured at 450 nm on a 
SpectraMax 190 microplate reader (Molecular Devices). Protein concentrations were calculated 
based on absorbance readings of a serial dilution of TGFβ1 protein of known concentration. 
 
Statistical analysis: Statistical analysis was performed using GraphPad Prism software (San 
Diego, CA). To determine significant main effects and interactions between variables, two- or 
three-way analysis of variance (ANOVA) was performed. Comparison between groups was 
performed using Student’s t-test and Bonferroni’s correction for multiple comparisons. A value of 
P < 0.05 was considered statistically significant. All data are presented as mean ± standard error 
of the mean (SEM). 
 
RESULTS 
Astrocyte-specific Il10ra knockout impairs propagation of a functional TGFβ response. 
Previous work from our lab and others have implicated impairment of IL-10/TGFβ signaling 
between microglia and astrocytes as a critical contributor to age-associated prolonged and 
exaggerated neuroinflammation stemming from unresolved microglial activation [32, 35, 37]. 
Accordingly, we sought to further characterize mechanisms of this pathway and potential 
therapeutic methods to attenuate detrimental neuroinflammation. Our first objective was to 
develop and maintain a transgenic mouse breeding colony to produce a Cre+ (and Cre- control) 
Il10raf/ox/flox line allowing inducible Il10ra knockout as an in vivo murine model of age-associated 
IL-10 receptor insensitivity [37]. Cre+ and Il10ra knockout are interchangeably synonymous in 
this study for the Cre+ Il10raflox/flox genotype. Tamoxifen was administered to induce Cre/lox 
recombination, excising floxed Exon 3 of the IL-10 receptor and rendering it dysfunctional (Fig. 
1A). Reporter strains were imaged with Evos fluorescent microscopy, where robust expression of 
tdTomato fluorescent protein reflected viable and effective induction of Cre/lox recombination 
(Fig. 1B).  
Cre- and Cre+ test subjects were injected (i.p.) with LPS or saline and sacrificed 4 h and 24 
h post-injection. Quantification of Il10ra expression via qPCR revealed distinct genetic profiles 
between brain slice mRNA and astrocyte mRNA at t = 24 h. Fold change of Il10ra was relatively 
uniform across all groups in the whole brain, with no significant differences, whereas a main effect 
of LPS (F(1, 16) = 5.25, P < 0.05) and trend by knockout (F(1, 16) = 3.278, P < 0.09) existed in 
the astrocyte profile (Fig. 1C). Post hoc analysis revealed that LPS-treated Cre+ subjects express 
lower Il10ra compared to both genotype-matched saline controls (t(16) = 3.34, P < 0.01) and 
treatment-matched Cre- controls (t(16) = 3.00, P < 0.05), reflecting astrocyte-specific knockout of 
Il10ra following peripheral immune challenge in Cre+ Il10raflox/flox mice. To assess the downstream 
effects of Il10ra knockout on IL-10/TGFβ signaling, we then quantified astrocytic Tgfb1 
expression with qPCR, finding a non-significant trend of decreased Tgfb1 in LPS-treated mice at 
t = 4 h, followed by a main effect of knockout (F(1, 16) = 6.81, P < 0.05) and a trend by LPS (F(1, 
16) = 3.19, P < 0.10) on Tgfb1 expression at t = 24 h (Fig. 1D). Moreover, post hoc analysis 
revealed lower expression of Tgfb1 in LPS-treated Cre+ mice compared to both genotype-matched 
saline controls (t(16) = 3.24, P < 0.05) and treatment-matched Cre- controls (t(16) = 3.83, P < 
0.01). Taken together, the tamoxifen induction of the Cre+ Il10raflox/flox genotype functionally 
knocks out Il10ra, impairing astrocytic production of TGFβ following the acute phase of LPS-
induced peripheral immune challenge. 
 
Impairment of TGFβ-mediated attenuation facilitates acute microglial activation and 
exaggerated sickness behavior 4 hours after peripheral immune challenge. With a viable in 
vivo transgenic murine model (Fig. 2A), we sought to further elucidate genetic and functional 
consequences of astrocytic Il10ra knockout and impaired TGFβ production on the inflammatory 
profile of the brain microenvironment in the acute phase of activation following LPS injection [7, 
20, 24, 26, 27]. Tamoxifen-induced Cre+ and Cre- Il10raflox/flox mice were given i.p. LPS or saline 
injections and sacrificed at t = 4 h (Fig. 2B). qPCR analysis of Percoll-enriched microglia revealed 
main effects of knockout (F(1, 11) = 6.18, P < 0.05) and LPS (F(1, 11) = 189.40, P < 0.0001), as 
well as an interaction effect between knockout and LPS (F(1, 11) = 7.10, P < 0.05), on expression 
of pro-inflammatory cytokine Il1b expressed as fold change. Additional post hoc analysis showed 
a significant increase compared to genotype-matched saline controls (t(11) = 11.19, P < 0.0001) 
and treatment-matched Cre- controls (t(11) = 3.79, P < 0.01) for LPS-injected Cre+ Il10raflox/flox 
mice (Fig. 2C). There was a main effect of LPS on Tnf expression (F(1, 12) = 41.60, P < 0.0001). 
Accordingly, Tnf expression was significantly lower compared to genotype-matched saline 
controls for both Cre- (t(12) = 5.35, P < 0.001) and Cre+ (t(12) = 3.78, P < 0.01) LPS-injected 
mice. Gene analysis of representative brain slices via qPCR revealed a main effect of LPS (F(1, 
15) = 4.73, P < 0.05) and a trend of knockout (F(1, 15) = 3.38, P < 0.09) on expression of reactive 
astrocyte marker Gfap (Fig. 2D). Social exploratory behavior was recorded and analyzed at t = 0 
h and 4 h to assess functional consequences of Il10ra knockout (Fig. 2E). There were significant 
main effects of LPS (F(1, 67) = 41.88, P < 0.0001) and knockout (F(1, 67) = 8.04, P < 0.01) on 
social interaction at t = 4 h (Fig. 2F). Notably, social interaction of LPS-injected Cre+ mice was 
significantly decreased compared to genotype-matched saline controls (t(67) = 5.42, P < 0.0001) 
and treatment-matched Cre- controls (t(67) = 2.91, P < 0.01). Comprehensive analysis at t = 4 h 
following LPS injection reveals an acute inflammatory signature characterized by glial activation 
(Fig. 2C, D) and social withdrawal (Fig. 2F) that was further exacerbated by astrocytic Il10ra 
knockout. 
 
Prolonged microglial neuroinflammation persists in an IL-10RαA-cKO murine model 24 hours 
post-peripheral immune challenge. Peripheral innate immune challenge induces 
neuroinflammation and sickness response that is both exaggerated and prolonged in the aged brain 
[7, 22, 24, 27]. Thus, we aimed to characterize the consequences of Il10ra knockout on resolution 
of peripherally induced neuroinflammation over time by analyzing the genetic profile of Cre- and 
Cre+ Il10raflox/flox 24 h after i.p. injection of saline or LPS (Fig. 3A, B). There were significant 
main effects of LPS (F(1, 31) = 151.60, P < 0.0001) and knockout (F(1, 31) = 27.91, P < 0.0001), 
as well as a significant interaction effect between LPS and knockout (F(1, 31) = 24.43, P < 0.0001), 
on microglial Il1b expression at t = 24 h (Fig. 3C). Further post hoc analysis revealed a significant 
increase in Il1b fold change in LPS-injected Cre+ mice compared to genotype-matched saline 
controls (t(31) = 12.02, P < 0.0001) and treatment-matched Cre- controls (t(31) = 7.12, P < 0.0001). 
Similarly, there were significant main effects of LPS (F(1, 31) = 54.23, P < 0.0001) and knockout 
(F(1, 31) = 6.09, P < 0.05), as well as an interaction effect between LPS and knockout (F(1, 31) = 
7.43, P < 0.05), on microglial Tnf expression at t = 24 h (Fig. 3C). Post hoc analysis revealed a 
significant increase in Tnf fold change in LPS-injected Cre+ mice compared to genotype-matched 
saline controls (t(31) = 7.03, P < 0.0001) and treatment-matched Cre- controls (t(31) = 3.62, P < 
0.01). qPCR analysis of brain slice mRNA was conducted to profile the broader brain 
microenvironment. There was a main effect of LPS on Gfap expression (F(1, 32) = 12.56, P < 
0.01). Moreover, LPS-injected Cre+ mice had lower Gfap compared to genotype-matched saline 
controls (t(32) = 3.97, P < 0.001) and a trend of decrease compared to treatment-matched Cre- 
controls (t(32) = 2.34, P < 0.06) (Fig. 3D). Reactive astrocyte marker Vim was also quantified via 
qPCR and expressed as fold change. There were main effects of LPS (F(1, 16) = 9.56, P < 0.01) 
and knockout (F(1, 16) = 5.68, P < 0.05), as well as an interaction effect between LPS and 
knockout (F(1, 16) = 6.75, P < 0.05), on Vim expression at t = 24 h (Fig. 3D). Post hoc analysis 
further identified significant increase in Vim expression in LPS-injected Cre+ mice compared to 
genotype-matched saline controls (t(16) = 4.02, P < 0.01) and treatment-matched Cre- controls 
(t(16) = 3.52, P < 0.01). These data together reveal an prolonged inflammatory profile of glial 
activation at t = 24 h that reflects an inability of Cre+ Il10raflox/flox knockout mice to properly 
resolve microglial activation and attenuate exaggerated neuroinflammation. 
 
Unresolved Il10ra knockout-mediated microglial activation and neuroinflammation 
underlies prolonged social withdrawal sickness behavior. Peripheral challenge of the aged 
innate immune system elicits exaggerated and prolonged neuroinflammation that is associated with 
prolonged depressive-like sickness behavior [7, 39]. Our study assessed whether transgenic 
astrocytic Il10ra knockout recapitulated age-associated prolonged sickness behavior mediated by 
IL-10Rα insensitivity [37]. Body masses of saline- or LPS-injected Cre- or Cre+ mice were 
recorded at t = 0 h and t = 24 h to assess change in body weight. There were main effects of LPS 
(F(1, 32) = 161.30, P < 0.0001) and knockout (F(1, 32) = 6.45, P < 0.05), as well as an interaction 
effect between LPS and knockout (F(1, 32) = 10.89, P < 0.01), on change in body mass (Fig. 4A). 
Furthermore, LPS-injected Cre+ mice displayed greater magnitude of weight loss compared to 
genotype-matched saline controls (t(32) = 11.32, P < 0.0001) and treatment-matched Cre- controls 
(t(32) = 4.13, P < 0.001). This corresponded with food consumption measurements, where there 
were main effects of LPS (F(1, 32) = 116.40, P < 0.0001) and knockout (F(1, 32) = 5.94, P < 0.05), 
as well as an interaction effect between LPS and knockout (F(1, 32) = 4.81, P < 0.05, Fig. 4B). 
Post hoc analysis revealed lower food consumption in LPS-injected Cre+ mice compared to 
genotype-matched saline controls (t(32) = 9.18, P < 0.0001) and treatment-matched Cre- controls 
(t(32) = 3.27, P < 0.01). There were also main effects of LPS (F(1, 32) = 10.02, P < 0.01) and 
knockout (F(1, 32) = 5.35, P < 0.05), as well as an interaction effect between LPS and knockout 
(F(1, 32) = 4.88, P < 0.05), on nesting behavior (Fig. 4C). LPS-injected Cre+ mice utilized less 
nestlet material than genotype-matched saline controls (t(32) = 3.80, P < 0.01) and treatment-
matched Cre- controls (t(32) = 3.20, P < 0.01). Social index was analyzed as previously described, 
eliciting main effects of LPS (F(1, 32) = 4.82, P < 0.05) and knockout (F(1, 32), P < 0.01, Fig. 
4D). Knockout of Il10ra exacerbated sickness response, as LPS-injected Cre+ mice had a 
significantly lower social index than treatment-matched Cre- mice (t(32) = 3.03, P < 0.01). Social 
exploratory behavior was also expressed in a time-course format (Fig. 4E), where there were main 
effects of LPS and knockout at t = 4 h (F(1, 67) = 41.88, P < 0.0001 and F(1, 67) = 8.04, P < 0.01, 
respectively) and t = 8 h (F(1, 32) = 6.11, P < 0.05 and F(1, 32) = 6.27, P < 0.05, respectively), 
with a main effect of knockout at t = 24 h (F(1, 32) = 6.91, P < 0.05), on social interaction. LPS-
injected Cre+ mice exhibited less social interaction compared to genotype-matched saline controls 
and treatment-matched Cre- controls at both t = 4 h (t(67) = 5.42, P < 0.0001 and t(67) = 2.91, P 
< 0.01, respectively) and t = 8 h (t(32) = 2.51, P < 0.05 and t(32) = 2.53, P < 0.05, respectively). 
Overall, Il10ra knockout exacerbates an LPS-induced sickness response and mediates an inability 
to resolve prolonged and exaggerated microglial activation, underlying a poor recovery time-
course in social exploratory behavior. 
 
Viral Tgfb1 administration circumvents IL-10 receptor insensitivity and augments TGFβ 
expression in aged mice. To complement elucidation of the genetic and behavioral consequences 
of IL-10Rα knockout, we sought to identify a potential therapeutic approach to IL-10/TGFβ-
mediated breakdown in astrocytic attenuation of microglial neuroinflammation. We utilized 
adeno-associated virus (AAV) mediated gene therapy with hybrid serotype AAV2/5 to deliver 
mutant Tgfb1 to hippocampal astrocytes with high transduction efficiency [40]. Adult (6-8 wks) 
and aged (16-18 mos.) male BALB/c mice received bilateral intra-cerebral injections of AAV-
GFP (control) or AAV-TGFβ and allowed three weeks of virus transduction, followed by i.p. 
injection of saline or LPS at t = 0 h (Fig. 5A, B). Social exploratory behavior was assessed at t = 
0, 4, 8, and 24 h, and subjects were sacrificed and cells harvested for gene analysis at t = 24 h. 
Fluorescent histological imaging of immunostained coronal brain slices revealed robust expression 
of green fluorescent protein (GFP) in both adult and aged mice, reflecting efficient, astrocyte-
specific transduction of the AAVs (Fig. 5C). Due to COVID-19 research shutdowns, sample sizes 
of the AAV experiments were insufficient for conclusive statistical analyses, as determined by a 
power analysis. Percoll-enriched astrocytes were processed for mRNA isolation, reverse 
transcription, and qPCR analysis. There were non-significant differences in Il10ra expression 
across AAV-GFP and AAV-TGFβ groups, indicating the virus circumvented the Il10ra 
insensitivity of aged mice (Fig. 5D) to augment TGFβ. Augmentation was evident at both the 
genetic and functional level of TGFβ expression. There was a robust increase in Tgfb1 mRNA fold 
change for all AAV-TGFβ groups compared to age- and vector-matched AAV-GFP controls (Fig. 
5E). An ELISA assay of functional TGFβ1 protein yielded corresponding increases in AAV-TGFβ 
mice compared to treatment-matched AAV-GFP controls (Fig. 5F). Viral administration of AAV-
TGFβ augments expression of Tgfb1 mRNA and TGFβ1 protein in an Il10ra-independent manner. 
Augmentation of TGFβ ameliorates microglial activation and subsequent age-associated 
sickness behavior. Genetic and behavioral assays were conducted and analyzed to assess 
functional outcomes of TGFβ augmentation. As previously described (Fig. 5A, B, C), AAV-GFP 
or AAV-TGFβ were administered to adult and aged male BALB/c mice via intra-cerebral 
injection, followed by i.p. injection of saline or LPS. Microglial Il1b and Tnf were quantified with 
qPCR to characterize the pro-inflammatory signature (Fig. 6A). Both genes were increased in LPS-
injected mice compared to age- and vector-matched saline controls. Additionally, pro-
inflammatory signatures were heavily exacerbated in aged mice administered AAV-GFP control 
virus, while AAV-TGFβ administration ameliorated exaggerated inflammation and restored Il1b 
and Tnf expression levels to adult baselines. qPCR analysis of hippocampal tissue, where the virus 
was injected and concentrated, these trends were recapitulated in Il1b expression, with aged AAV-
GFP mice expressing robust increase in fold change that is rescued with AAV-TGFβ 
administration (Fig. 6B). Behavioral assays revealed a corresponding interaction. Aged mice 
administered AAV-GFP and challenged with LPS exhibited the most weight loss, a trend reversed 
by administration of AAV-TGFβ (Fig. 6C). Social index analysis revealed a markedly low level 
of social interaction in aged LPS-injected AAV-GFP mice that was rescued with AAV-TGFβ 
administration (Fig. 6D). A 24h time course of social exploratory behavior showed acute decrease 
in social interaction of aged LPS-injected AAV-GFP mice followed by an inability to recover to 
baseline levels over time (Fig. 6E). Administration of AAV-TGFβ to age- and LPS-matched mice 
elicited less exaggerated social sickness behavior at t = 4 h and improved recovery outcomes over 
time. The hyper-inflammatory genetic signature of aged mice challenged with LPS underlie 
exaggerated sickness behavior that is ameliorated with AAV-TGFβ-mediated gene therapy. 
 
DISCUSSION 
This study sought to characterize the IL-10/TGFβ signaling pathway between microglia and 
astrocytes and its implications in age-associated neuro-immune dysfunction. Our primary 
objectives were to determine whether IL-10Rα dysfunction is necessary and sufficient to induce 
prolonged and exaggerated microglial neuroinflammation and sickness behavior, and whether 
viral augmentation of TGFβ is sufficient to mitigate this dysfunction and attenuate the age-
associated breakdowns in neuro-immune response to peripheral immune challenges. 
We established the viability of a transgenic murine Il10ra knockout model to recapitulate 
aged-like deficits in Il10ra expression. Cre/lox site-specific recombination enabled the 
development of an Aldh1l1-CreERT2+ Il10raflox/flox line that induced Il10ra knockout upon tamoxifen 
administration (Fig. 1A). The selection of Aldh1l1-Cre recombinase leveraged Aldh1l1 as an 
established pan-astrocyte marker to induce highly efficient and astrocyte-specific knockout [41, 
42]. Indeed, non-significant differences in Il10ra expression across groups in whole brain tissue 
contrasted with a significant decrease in Il10ra expression in an astrocyte assay of LPS-injected 
Cre+ mice (Fig. 1C). This pointed to an astrocyte-specific induction of Il10ra knockout, although 
there was not a significant main effect of knockout. This could be mitigated with an alternative 
quantification method, such as quantifying co-localization of Sox9/pStat3 via histological 
immunochemistry analysis or quantifying Il10ra expression of GLAST+ astrocytes via flow 
cytometry, as qPCR quantification of Il10ra presents difficulty due to a low baseline expression 
of Il10ra from cortical astrocytes. Previous work from our lab has shown that astrocyte cytokine 
induction is delayed in comparison to microglial proinflammatory cytokine expression [20]. 
Moreover, TGFβ expression does not reach its peak until t = 12 h following LPS challenge. Indeed, 
following Il10ra dysfunction, astrocytic Tgfb1 expression was undifferentiated across groups at t 
= 4 h, but was significantly lower for Cre
+ knockout mice compared to treatment-matched Cre- 
mice at t = 24 h (Fig. 1D). Tgfb1 expression emulated the previously established sequential 
timeframe, increasing after the acute inflammation phase at t = 4 h following peripheral immune 
challenge to resolve microglial activation, with the exception of Il10ra knockout mice, which 
displayed impaired TGFβ signaling. 
 Transgenic knockout of Il10ra effectively disrupted homeostatic IL-10/TGFβ signaling 
and impaired TGFβ-mediated anti-inflammatory response to microglial activation following the 
acute stage of LPS immune challenge. Thus, we sought to further elucidate the neurobehavioral 
profile at various timepoints encompassing the acute and prolonged phases of lipopolysaccharide-
induced neuroinflammation [34, 37]. We began with the t = 4 h timepoint, representative of the 
acute phase. A robust increase in microglial expression of pro-inflammatory cytokine Il1b from 
saline controls to LPS-injected mice was further exacerbated by Il10ra knockout, emulating aged-
like exaggeration of microglial inflammation with Il10ra dysfunction (Fig. 2C). A main effect of 
LPS was also observed in Tnf expression but did not follow the same pattern of knockout-mediated 
exacerbation. This points to the possibility of an Il1b-mediated acute neuroinflammatory response 
to IL-10/TGFβ signaling impairment. A main effect of LPS on expression of Gfap, a marker of 
astrocyte reactivity [43], accompanied by a marked upregulation of Gfap in LPS-injected knockout 
subjects signified a shift toward a reactive astrocyte profile (Fig. 2D). Notably, previous work 
reported absence of GFAP immunoreactivity following LPS administration [20], indicating this 
increase in astrocyte reactivity is knockout-mediated. These genetic profiles aligned with 
concomitant social exploratory behavior testing, which revealed a significant decrease in social 
interaction at the acute timepoint following LPS administration, which was further exacerbated by 
Il10ra knockout (Fig. 2F). Taken together, these gene and behavioral data reflect an acute 
neurobehavioral response of Il10ra knockout mice to peripheral immune challenge at t = 4 h. 
Previous studies have reported the transient nature of the acute LPS response, followed by 
rapid recovery from sickness 24-48 h post-injection [7, 20, 26]. However, age-associated deficits 
result in a prolonged period of neuroinflammation and impaired resolution of microglial activation 
[4, 22, 27]. Accordingly, we conducted gene and behavioral assays at t = 24 h following LPS 
injection to study the recovery profile of Il10ra knockout mice. We hypothesized that they would 
recapitulate an aged-like phenotype of persistent microglial neuroinflammation and prolonged 
sickness behavior. Indeed, microglial expression of pro-inflammatory cytokines Il1b and Tnf 
revealed similar profiles of prolonged increase at t = 24 h in LPS-injected groups, an escalation 
significantly further exacerbated by Cre+ Il10ra knockout (Fig. 3C). Notably, Tnf expression in 
the LPS-injected Cre+ group was significantly increased compared to treatment-matched Cre- 
controls (P < 0.01), an effect that was not present at the t = 4 h timepoint. This points to a delayed 
interaction effect between LPS and knockout in exacerbating Tnf contribution to 
neuroinflammation. Moreover, fold change levels were lower across the LPS groups at t = 24 h 
compared to the t = 4 h, reflecting an overall profile of recovery; however, as expected, this 
recovery is impaired in the Cre+ knockout group in the form of prolonged microglial 
neuroinflammation. Gene analysis of representative whole brain tissue revealed increased Gfap 
and Vim expression with concomitant LPS injection and Il10ra knockout. Previous work from our 
lab has provided evidence that GFAP immunoreactivity of astrocytes in the hippocampus is 
unaffected after LPS challenge [20]. While reactive astrogliosis mediated by intermediate 
filaments such as GFAP and vimentin serves important neuroprotective roles in response to acute 
stressors such as CNS injury and trauma, the same astrocytic reactivity has been associated with 
aging and neuroinflammatory pathologies, making it a marker of interest [43, 44, 45, 46, 47, 48, 
49]. Furthermore, the degree of GFAP immunoreactivity in the aged brain has been positively 
linked with extent of cognitive impairment [50]. Significantly lower Gfap and Vim expression in 
LPS-injected Cre+ knockout mice compared to matched saline and Cre- controls provided evidence 
that interaction between LPS and Il10ra knockout induces aged-like hyperreactivity in astrocytes 
(Fig. 3D). Taken together, these genetic data characterize a persistent hyperinflammatory signature 
at t = 24 h following peripheral immune challenge, mediated by impaired resolution of microglial 
activation. 
We then assessed social exploratory behavior, weight loss, nesting behavior, and food 
consumption for evidence of neuroinflammation-associated sickness behavior emulating an aged-
like phenotype. Here, we provide evidence of exacerbated behavioral deficits in LPS-injected Cre+ 
Il10ra knockout mice indicative of neuroinflammation-induced prolonged sickness behavior. 
There were significant main effects of LPS and knockout, as well as interaction effects between 
the two variables for weight change, food consumption, and nesting behavior, for each of the 
behavioral assays conducted (Fig. 4). Furthermore, LPS-injected Il10ra knockout mice exhibited 
significantly more weight loss, less food consumption, less nesting behavior, and less social 
interaction expressed as social index compared to their LPS-injected Cre- counterparts. This robust 
difference by genotype underscores an Il10ra knockout-mediated exacerbation of sickness 
behavior that recapitulates age-associated prolonged depressive-like and social withdrawal 
behavior. Closer examination of a full 24 h time-course of social behavioral response to LPS 
immune challenge provides a visual representation of exaggerated sickness behavior at the acute 
time point (t = 4 h) followed by an impaired and prolonged recovery through the 8 and 24 h 
timepoints in LPS-injected Cre+ Il10ra knockouts (Fig. 4E). The persistent exacerbation of 
microglial neuroinflammation at t = 24 h underlies Il10ra dysfunction-mediated prolongation of 
sickness behavior through t = 24 h following peripheral immune challenge. 
Following the recapitulation of an aged-like phenotype of prolonged and exaggerated 
neuroinflammation underlying sickness behavior in an in vivo Il10ra knockout model, we sought 
to identify a viable targeted gene therapy to mitigate age-associated Il10ra dysfunction. We 
employed adeno-associated virus (AAV) to deliver gene therapy to astrocytes in the hippocampus, 
achieving high efficiency and specificity with the hybrid serotype AAV2/5 and a GFAP(0.7) 
promoter [40]. The control AAV-GFP virus (AAV2/5-GFAP(0.7)-eGFP) exclusively expressed 
enhanced green fluorescent protein (eGFP), whereas the experimental AAV-TGFβ virus 
(AAV2/5-GFAP(0.7)-mTGFb1(C223S/C225S)-IRES-GFP) expressed eGFP as well as mutant 
Tgfb1 that yielded biologically active TGFβ1 (Fig. 5A, C). The AAV-mediated gene therapy 
transduced Tgfb1 mRNA and induced production of functional TGFβ1 protein in an Il10ra-
independent manner (Fig. 5D). Increase of Tgfb1 and TGFβ1 was robust and present across all age 
and LPS treatment groups administered AAV-TGFβ, demonstrating substantial ubiquitous 
hippocampal augmentation of TGFβ with AAV-mediated gene therapy (Fig. 5E, F). 
We hypothesized TGFβ augmentation was sufficient to mitigate consequences of age-
associated Il10ra dysfunction and attenuate prolonged and exaggerated neurobehavioral 
signatures. Indeed, microglial expression of Il1b and Tnf were heightened with LPS and 
exacerbated by age when administered the AAV-GFP vector. However, administration of AAV-
TGFβ ameliorated this age-associated hyperinflammation, with expression levels emulating adult-
like profiles (Fig. 6A). Analysis of the microenvironment of the hippocampus produced a similar 
profile, with significantly heightened Il1b expression in LPS-injected aged AAV-GFP mice 
attenuated in matched AAV-TGFβ mice (Fig. 6B). Weight loss and social index assays followed 
this AAV-mediated exacerbation/attenuation contrast (Fig. 6C, D). A 24 h time-course showed 
acute social exploratory behavioral deficits in the aged AAV-GFP LPS group with an ensuing 
impaired recovery of baseline social interaction (Fig. 6E). Administration of AAV-TGFβ in an 
age- and LPS-matched group yielded markedly less acute sickness behavior at t = 4 h and improved 
recovery through 24 h. Taken together, we provide novel evidence that the augmentation of TGFβ 
via AAV-mediated gene therapy mitigates age-associated prolongation and exaggeration of 
microglial neuroinflammation and resolves exacerbation of sickness behavior. 
As previously discussed, future investigation will supplement our study of AAV2/5-
mediated gene therapy with additional cohorts to increase n and achieve sufficient sample sizes as 
dictated by a power analysis, upon reinstatement of laboratory research following COVID-19 
closures. Future studies will also seek to elucidate the intracellular and downstream signaling 
mechanisms that contribute to age-associated dysfunction and corresponding mitigation of the IL-
10/TGFβ pathway. Single-cell RNA sequencing (scRNA-seq) will aim to reveal genes and 
canonical pathways of interest in a study of the 4 h and 24 h timepoints of LPS immune challenge 
of aged mice, as well as distributions and characteristics of distinct glial populations [51]. The vast 
array of data produced by such experimentation will provide an in-depth, multi-layered analysis 
of genes and cell types implicated in the IL-10/TGFβ pathway and age-associated alteration of 
neuro-immune functions. We will also be conducting immunohistochemistry for quantifiable 
histological analysis of glial interactions in a transgenic Il10ra knockout model and AAV-TGFβ 
gene therapy model. Optimizing longevity and increasing health spans for an aging population 
begins with mitigating development of physiological impairment to preserve healthy function [52]. 
We aim to comprehensively characterize the IL-10/ TGFβ pathway and its viability as a potential 
therapeutic target for resolving age-associated neuroimmune dysfunction in elderly individuals. 
 
CONCLUSION 
In this study we provided novel evidence that Il10ra dysfunction is necessary and sufficient to 
induce an aged-like phenotype of prolonged and exaggerated neuroinflammation with sickness 
behavioral consequences. Knockout of astrocytic Il10ra impairs TGFβ-mediated regulation of 
microglia, facilitating an exaggerated inflammatory neurobehavioral signature during the acute 
phase and persistent impairment of neuroinflammation attenuation through 24 hours following 
peripheral immune challenge. Moreover, the age-associated hyperinflammatory profile is 
attenuated with adeno associated virus-mediated gene therapy delivery of mutant Tgfb1 to augment 
TGFβ signaling. Genetic and behavioral consequences of age-associated exacerbation of 
neuroinflammation resulting from Il10ra dysfunction are mitigated by AAV-TGFβ-mediated 
resolution of microglial activation. Taken together, these data implicate the IL-10/TGFβ pathway 
as a key mediator of age-associated neuroimmune dysfunction and potential therapeutic target for 
improving longitudinal clinical outcomes of acute peripheral infections for a rapidly growing 
geriatric population. 
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FIGURE LEGENDS 
Figure 1. Astrocyte-specific Il10ra knockout impairs propagation of a functional TGFβ 
response. Cre/lox recombination was utilized to produce an IL-10RαA-cKO line allowing for 
conditional, astrocyte-specific knockout of IL-10 receptor upon tamoxifen administration. (A) 
Aldh1l1-CreErT2 mice were crossed with IL-10Rαflox mice to ‘flox’ out Exon 3 of Il10ra and 
inhibit functionality of IL-10 protein. (B) Induction of tamoxifen and verification of Cre/lox 
recombination were confirmed with representative immunohistochemistry imaging of tdTomato 
reporter mice. (C) Adult (8 wks) Cre- (control) and Cre+ (Il10ra knockout) mice were given 
intraperitoneal (i.p.) injections of saline or 0.50 mg/kg LPS (n = 9 mice/group) and processed for 
Percoll-enriched glial cells (as previously described) and representative brain slices 4 h and 24 h 
post-injection. Expression levels of Il10ra were analyzed from glial and brain tissue via qPCR at 
t = 24 h. (D) Expression levels of Tgfb1 mRNA were measured by qPCR as fold change from a 
control group at t = 4 h and t = 24 h, respectively. Means with † denote P < 0.05 compared to the 
genotype-matched saline control group. Means with * denote P < 0.05 compared to the treatment-
matched Cre- group. 
 
Figure 2. Impairment of TGFβ-mediated attenuation facilitates acute microglial activation 
and exaggerated sickness behavior 4 hours after peripheral immune challenge. (A) Male 
adults from the IL-10RαA-cKO line (as previously described) and Cre- controls were administered 
1.5 mg i.p. tamoxifen in corn oil (10 mg/mL) daily for five days to induce Il10ra knockout. (B) 
Diagram of experimental design with t = 4 h endpoint. In brief, adult (8 wks) male Cre- (control) 
and Cre+ (Il10ra KO) mice were given i.p. injections of saline or 0.50 mg/kg LPS (n = 9 
mice/group) and sacrificed 4 h post-injection for harvesting and processing of coronal brain 
sections and Percoll-enriched glia. Social exploratory behavior was analyzed at t = 0 h and t = 4 h 
post-injection. (C) As previously described, microglia were isolated from the 50/70 interface of a 
Percoll density gradient of brain tissue homogenate. mRNA was isolated from Percoll-enriched 
microglia using the RNeasy Mini Plus Kit and reversed transcribed to produce cDNA. qPCR was 
performed to analyze microglial gene expression of pro-inflammatory cytokines Il1b and Tnf; 
results were expressed as fold change from controls. (D) Representative 1-mm coronal brain 
sections were taken from each mouse and processed for mRNA through Tri-Reagent isolation 
protocol, followed by reverse transcription as previously described. Expression of reactive 
astrocyte marker Gfap was analyzed and expressed as fold change. (E) Diagram of social 
exploratory behavior paradigm. In brief, experimental subjects were allowed 5 minutes of open-
field exploration, followed by introduction of a novel male juvenile mouse into their home cage 
for 5 additional minutes. Social investigation was assessed by duration of time spent investigating 
the novel mouse. (F) Social exploratory behavior was expressed as social interaction time at the t 
= 4 h timepoint normalized to baseline (t = 0 h) behavior activity. Means with † denote P < 0.05 
compared to the genotype-matched saline control group. Means with * denote P < 0.05 compared 
to the treatment-matched Cre- group. 
 
Figure 3. Prolonged microglial neuroinflammation persists in an IL-10RαA-cKO murine model 
24 hours post-peripheral immune challenge. (A) Male adults from the IL-10RαA-cKO line 
(previously described) and Cre- controls were administered 1.5 mg i.p. tamoxifen in corn oil (10 
mg/mL) daily for five days to induce Il10ra knockout. (B) Diagram of experimental design with t 
= 24 h endpoint. In brief, adult male Cre- and Cre+ were given i.p. injections of saline or 0.50 
mg/kg LPS (n = 9 mice/group) and sacrificed 24 h post-injection. Coronal brain sections (1-mm, 
Bregma – 1.5 mm) were harvested, with remaining brain tissue homogenized and layered with 
Percoll density gradients to isolate microglia. Social exploration behavior was recorded and 
analyzed at t = 0 h, 4 h, 8 h, and 24 h post-injection for interaction time and social index. Fresh 
nestlets were weighed and placed in home cages of test subjects at t = 0 h and weighed at t = 24 h 
to assess nesting behavior. Masses of test subjects and their food were recorded at t = 0 h and t = 
24 h to assess sickness-associated weight and diet changes, respectively. (C) Percoll-enriched 
microglia were processed to produce cDNA, as previously described. qPCR was performed to 
analyze microglial gene expression of pro-inflammatory cytokines Il1b and Tnf and results were 
expressed as fold change from a control group. (D) mRNA was isolated from coronal brain sections 
with Tri-Reagent as previously described and reverse transcribed to prepare cDNA for qPCR 
analysis. Reactive astrocyte markers Gfap and Vim were analyzed as fold change from a control 
group to assess astrocyte reactivity in the brain microenvironment. Means with † denote P < 0.05 
compared to the genotype-matched saline control group. Means with * denote P < 0.05 compared 
to the treatment-matched Cre- group. 
 
Figure 4. Unresolved knockout-mediated microglial activation and neuroinflammation 
underlies prolonged social withdrawal sickness behavior. (A) As previously described, body 
masses of test subjects were recorded 0 h and 24 h post-injection to assess sickness-associated 
weight changes. (B) Masses of standard rodent chow were recorded at t = 0 h and t = 24 h to assess 
sickness-associated differences in food consumption. (C) At t = 8 h, nests in each home cage were 
replaced with a fresh cotton nestlet. The mass of the nestlet was recorded at t = 8 h and t = 24 h to 
assess differences in nesting behavior as an indicator of prolonged sickness. (D) Social exploration 
behavior was assessed 0 h, 4 h, 8 h, and 24 h post-injection as previously described. Social index 
was calculated as normalized area under the curve of social interaction as a function of time, with 
a higher value reflecting more time overall spent interacting with the introduced juvenile mouse. 
(E) A holistic time course of social interaction at each time point, normalized to baseline activity 
level. Means with † denote P < 0.05 compared to the genotype-matched saline control group. 
Means with * denote P < 0.05 compared to the treatment-matched Cre- group. 
 
Figure 5. Viral Tgfb1 administration circumvents IL-10 receptor insensitivity and augments 
TGFβ expression in aged mice. (A) Visual representation of the adeno-associated virus (AAV) 
vector for augmentation of TGFβ. Each vector was comprised of an AAV5 capsid and AAV2 ITR 
(AAV2/5 hybrid serotype). The experimental vector (AAV-TGFβ) expressed enhanced green 
fluorescent protein (eGFP) and Tgfb1; the control vector (AAV-GFP) expressed eGFP only. (B) 
Diagram of AAV2/5 experimental design. In brief, in a 2 x 2 x 2 factorial design, adult (6-8 wks) 
and aged (16-18 mo.) male BALB/c mice were administered AAV-GFP or AAV-TGFβ directly 
to the hippocampus (-1.82 mm AP, ±1.57 ML, +1.85 DV) in each hemisphere via stereotactic 
craniotomy and intra-cerebral injection (1010 GC per 2-μL). Three weeks thereafter, test subjects 
were given i.p. injections of 0.33 mg/kg LPS or saline (t = 0 h). As previously described, social 
exploratory behavior was recorded and analyzed at t = 0 h, 4 h, 8 h, and 24 h, with body masses 
recorded at t = 0 h and 24 h for weight change assessment. At t = 24 h, test subjects (n = 2 
mice/group) were sacrificed and hippocampi from each hemisphere were micro-dissected and 
frozen in liquid nitrogen, with remaining brain tissue processed for Percoll-enrichment and 
isolation of glia, as previously described. (C) Adult and aged AAV-GFP mice were sacrificed and 
brains transcardially perfused with 5 mL ice-cold PBS and fixed with 5 mL 4% paraformaldehyde. 
Brains were flash-frozen, cryosectioned, and prepared for fluorescent histological analysis via 
immunohistochemistry (1°: GFAP, 1:500, Abcam; 2°: Alexa Fluor 594, 1:500, Invitrogen), and 
imaged with EVOS Cell Imaging System fluorescence microscopy. (D) Astrocytes were isolated 
from the 35/50 interface of Percoll density gradient and processed for mRNA and cDNA. qPCR 
quantification of Il10ra mRNA was expressed as fold change from control group. (E) 
Hippocampal mRNA was isolated with Tri-Reagent protocol and reverse transcribed to cDNA for 
qPCR analysis. Expression level of Tgfb1 was measured as fold change from control group. (F) 
Hippocampal tissue was sonicated in Tissue Protein Extraction Reagent and TGFβ protein 
concentrations were determined with ELISA Kit PicoKineTM protocol and standardized for 
expression as mass (pg). 
 
Figure 6. Augmentation of TGFβ ameliorates microglial activation and subsequent age-
associated sickness behavior. Adult (6-8 wks) and aged (16-18 mo.) male BALB/c mice were 
administered AAV-TGFβ or AAV-GFP and 0.33 mg/kg LPS or saline, then sacrificed and 
processed at t = 24 h as previously described (n = 2 mice/group). (A) Percoll-enriched microglia 
were isolated from the 50/70 interface of a Percoll density gradient and processed with RNeasy 
Mini Plus kit to isolate mRNA. mRNA was reverse transcribed to produce cDNA for qPCR 
analysis. Pro-inflammatory microglial markers Il1b and Tnf were quantified and expressed as fold 
change from a control group. (B) Hippocampal cDNA was quantified by qPCR as previously 
described. Expression levels of Il1b was normalized as fold change from control group. (C) Body 
masses of test subjects were recorded at t = 0 h and 24 h and assessed for change (Δ) in body mass. 
(D) Social exploration behavior was recorded and analyzed at t = 0 h, 4 h, 8 h, and 24 h. Social 
index (SI) was calculated as normalized area under the curve of social interaction as a function of 
time, where higher SI values reflected higher social interaction levels. (E) A time course of social 
exploratory behavior by group over 24 h, normalized to baseline activity level.  
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